Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (129)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (13)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Associations between cancer predisposition mutations and clonal hematopoiesis in patients with solid tumors
    Journal Article

    Franch-Expósito, S.; Mehine, M.; Ptashkin, R. N.; Bolton, K. L.; Bandlamudi, C.; Srinivasan, P.; Zhang, L.; Goodell, M. A.; Gedvilaite, E.; Menghrajani, K.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Response to repotrectinib after development of NTRK resistance mutations on first- and second-generation TRK inhibitors
    Journal Article

    Chen, M. F.; Yang, S. R.; Shia, J.; Girshman, J.; Punn, S.; Wilhelm, C.; Kris, M. G.; Cocco, E.; Drilon, A.; Raj, N.
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer
    Journal Article

    Thummalapalli, R.; Bernstein, E.; Herzberg, B.; Li, B. T.; Iqbal, A.; Preeshagul, I.; Santini, F. C.; Eng, J.; Ladanyi, M.; Yang, S. R.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer
    Journal Article

    Sia, T. Y.; Maio, A.; Kemel, Y. M.; Arora, K. S.; Gordhandas, S. B.; Kahn, R. M.; Salo-Mullen, E. E.; Sheehan, M. A.; Tejada, P. R.; Bandlamudi, C.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Prevalence and clinical implications of mismatch repair-proficient colorectal cancer in patients with Lynch syndrome
    Journal Article

    Ranganathan, M.; Sacca, R. E.; Trottier, M.; Maio, A.; Kemel, Y.; Salo-Mullen, E.; Catchings, A.; Kane, S.; Wang, C.; Ravichandran, V.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Understanding genomic and social determinants of cancer immunotherapy outcome across ancestry
    Meeting Abstract

    Fong, C. J.; Waters, M.; Pichotta, K.; Jee, J.; Jutagir, D. R.; Ma, D.; Perea-Chamblee, T.; Kim, S.; Arora, K.; Mastrogiacomo, B.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: A narrative review
    Review

    Chen, M. F.; Chaft, J. E.
    Translational Lung Cancer Research (2023)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
    Meeting Abstract

    Shastri, A.; Feldman, E. J.; Starodub, A. N.; Feldman, T.; Rodriguez, C. P.; Epstein-Peterson, Z. D.; Stevens, D. A.; Olszewski, A. J.; Huen, A. O.; Porcu, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation
    Meeting Abstract

    Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative analysis of clinical outcomes and healthcare resource utilization (HRU) in patients (pts) with newly diagnosed (nd) acute myeloid leukemia (aml) unfit for high-intensity chemotherapy treated with venetoclax (VEN) vs other therapies: Results from the AML real world evidence (ARC) initiative
    Meeting Abstract

    Desai, P.; Garcia, J. S.; Zeidner, J. F.; Abedin, S.; Wolach, O.; Vachhani, P.; Moshe, Y.; Pollyea, D. A.; Lai, C.; LeBlanc, T. W.; more...
    Blood (2023)

    Fulltext@MSK | Save